Sihuan Pharmaceutical: If the performance of 2025 does not meet the standards, the company's stock may be delisted.

Sihuan Biology announced that starting from April 30, 2025, the company's stock will be subject to delisting risk warning. According to the "Stock Listing Rules", if one of the specified circumstances occurs after the disclosure of the 2025 annual report, the company's stock will face the risk of delisting. The company also disclosed a performance forecast on the same day, with an expected non-GAAP net profit for 2025 of -46 million to -33 million yuan, and a revenue of 3.3 billion to 3.5 billion yuan after deduction. These data have not been audited. Before the annual report disclosure, the company will disclose risk reminders every ten trading days.